Support that advances the work
A young company needs people willing to examine an idea before its full value is visible. NEUVIOR’s beginnings include competitive innovation support, specialist scientific input and the work of turning ambitious questions into defined programmes.
We are proud of that record and grateful to the organisations and people who helped it develop. Each milestone has a purpose: creating the time, capability or evidence needed to take the next step. Our story starts with medicines intelligence, then expands into the scientific and industrial questions that shape how medicine can be developed and delivered.
Ambition supported by opportunity
Competitive public funding has supported defined NEUVIOR programmes. We are grateful for the opportunity to turn research proposals into development and feasibility work.
Awards and support
Our first selection: 34 days after incorporation
The company behind NEUVIOR was incorporated on 4 August 2025. Founder Varun Sharma records receiving an early Growth Catalyst selection notification on 7 September 2025, 34 elapsed days later. The formal grant offer was dated 13 October 2025. The early notification and formal offer are separate moments in that chronology.
For a company at the beginning of its life, the early selection mattered. It gave a proposed medicines technology a defined opportunity to develop. The 34-day story belongs to the founder’s account of those beginnings; the public project record provides the award amount and funded period that followed.
What competitive selection means to us
Innovate UK’s Growth Catalyst: early stage, new innovators competition invited small UK businesses to develop innovations with commercial potential. Applications had to make a case for the proposed work, its value and the resources needed to investigate it.
Being selected gave NEUVIOR an early opening to pursue PHARMORIS within a funded project. It also sharpened the responsibility that follows support: define the question, carry out the work and use what is learned to make a better next decision. We value the confidence behind that opportunity and the discipline of having a project with a purpose and an end point.
PHARMORIS
The UKRI Gateway to Research record lists £49,928 from Innovate UK for PHARMORIS, with a funded period from November 2025 to April 2026. The project is recorded as closed. Its published title concerns generics optimisation for the NHS and global health.
That programme forms part of PHARMORIS’s software-development history. Our wider direction now centres on the Medicines Action Layer: connecting medicines evidence with a decision, an implementation plan and a useful review. The next evidence questions concern how that approach performs for a defined professional task and whether the resulting value justifies adoption in a particular organisation.
Support and development
What did early support make possible next?
Competitive support creates an opportunity to perform defined work. Explore the distinction between an early notification, a formal award, the activity it supports and the finding that still needs examination. The chronology gives the company’s beginnings context while keeping a selection decision separate from product or clinical validation.
Editorial decision model, not measured NEUVIOR results. Sources identify the published context; selected lenses do not establish product performance, customer adoption or institutional endorsement.
The early story needs its full chronology.
The early notification and formal award are separate moments. Keeping both visible gives the founder’s account context without compressing it into a stronger claim. The significance is the opportunity it opened and the responsibility to produce examinable work afterwards.
Which dated record explains the milestone you are discussing?
Early notification
The founder’s account records an early selection notification before the formal offer. That moment explains why the beginning mattered to a young company. It belongs to a dated chronology and should not replace the later award documentation or establish that the proposed work succeeded.
- Formalise scope
Founder chronology alongside the dated formal offer and public award record.
A useful next stepRead the dates as separate events rather than one award milestone.
Early support is valuable when its scope, work and next decision can be examined separately.
PHARMORIS-SCOT
Scottish Enterprise backing for PHARMORIS feasibility work was publicly reported in May 2026. The Scottish programme focuses on AI-assisted medicines prioritisation, evidence and dossier preparation, and modelling the practical conditions for generic-medicines adoption.
It asks a demanding question: what would an organisation actually need to know before acting on a medicines opportunity? A promising case must withstand expert review and the realities of local delivery. Scotland offers a focused context in which to investigate that question, with the next steps shaped by the quality of the evidence and the needs of the selected setting.
ZYLON
UKRI also records a £25,000 Innovate UK award under the earlier project name VIONIX ZERO, covering February to March 2026. That project is recorded as closed. It sits in the development history of ZYLON, our work on bio-derived materials and resource opportunities in pharmaceutical manufacturing.
ZYLON’s initial feasibility study is complete, with laboratory work involving the 
Biorenewables Development Centre in York. That stage gave the programme a more concrete basis for considering the next materials and process questions. Further development needs a clear industrial use, a suitable comparison and evidence that a proposed approach can justify its place in manufacturing.
From support to a development record
These programmes create different kinds of progress. Medicines software needs an assessable workflow and evidence of practical usefulness. A feasibility study needs to clarify what deserves further investigation. Materials work needs reproducible comparisons against relevant alternatives.
The next chapter of NEUVIOR’s record should show how those outputs change decisions. Which task is worth developing? Which result deserves another study? Which delivery model can be supported? Answering those questions well is how public support becomes a stronger company, a clearer research programme and a more credible proposition for future collaborators and investors.
A scientific programme needs more than a selection announcement: it needs a question, a method and a useful record. This illustrative glassware photograph is independent of the funded projects and does not show their equipment or results.
DC_Studio / Dragos Condrea · Science Lab Glassware with Dark Blue LightingEnvato Elements commercial licence
Source and image notes
Full frame retained; EXIF orientation honoured, proportionally resized and encoded as WebP. No crop, creative colour grading, compositing or generative changes.
Follow what comes next
Our ambition is to build a company whose work earns attention through useful products, rigorous investigations and a growing capacity to deliver. We will add milestones as their supporting records can be shared, with the programme, period and meaning of each achievement clear.
We welcome people who can help turn the next question into worthwhile work: a medicines organisation with a defined problem, a researcher with relevant expertise or an investor interested in the next stage. Tell us the programme and contribution you have in mind, so that the conversation can start with a real purpose.
